Literature DB >> 22507319

Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.

M Scarpelli1, R Mazzucchelli, F Barbisan, A Santinelli, A Lopez-Beltran, L Cheng, R Montironi.   

Abstract

Prostate Tumour Overexpressed-1 (PTOV1) was recently identified as a novel gene and protein during a differential display screening for genes overexpressed in prostate cancer (PCa). Alpha-Methyl-CoA racemase (AMACR) mRNA was identified as being overexpressed in PCa. PTOV1 and racemase were immunohistochemically evaluated in PCa, high-grade prostatic intraepithelial neoplasia (HGPIN), atrophy and normal-looking epithelium (NEp) in 20 radical prostatectomies (RPs) with pT2a Gleason score 6 prostate cancer with the aim of analyzing the differences in marker expression between PTOV1 and AMACR. The level of expression of PTOV1 and AMACR increased from NEp and atrophy through HGPIN, away from and adjacent to prostate cancer, to PCa. With the ROC curve analysis the overall accuracy in distinguishing PCa vs HGPIN away from and adjacent to cancer was higher for AMACR than for PTOV1. In conclusion, AMACR can be considered a more accurate marker than PTOV1 in the identification of HGPIN and of PCa. However, PTOV1 may aid in the diagnosis of PCa, at least to supplement AMACR as another positive marker of carcinoma and to potentially increase diagnostic accuracy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22507319     DOI: 10.1177/039463201202500109

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  5 in total

1.  Gene panel model predictive of outcome in patients with prostate cancer.

Authors:  Nadège Rabiau; Yann Dantal; Laurent Guy; Marjolaine Ngollo; Aslihan Dagdemir; Jean-Louis Kemeny; Benoît Terris; Annick Vieillefond; Jean-Paul Boiteux; Yves-Jean Bignon; Dominique Bernard-Gallon
Journal:  OMICS       Date:  2013-06-11

2.  Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate: additional evidence linking (AAH) to adenocarcinoma.

Authors:  Roberta Mazzucchelli; Marina Scarpelli; Francesca Barbisan; Alfredo Santinelli; Antonio Lopez-Beltran; Liang Cheng; Rodolfo Montironi
Journal:  Cell Oncol (Dordr)       Date:  2012-11-07       Impact factor: 6.730

3.  Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients.

Authors:  A Vral; V Magri; E Montanari; G Gazzano; V Gourvas; E Marras; G Perletti
Journal:  Int J Oncol       Date:  2012-10-01       Impact factor: 5.650

4.  Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma.

Authors:  Parag Deepak Dabir; Peter Ottosen; Søren Høyer; Stephen Hamilton-Dutoit
Journal:  Diagn Pathol       Date:  2012-07-16       Impact factor: 2.644

Review 5.  The role of prostate tumor overexpressed 1 in cancer progression.

Authors:  Verónica Cánovas; Matilde Lleonart; Juan Morote; Rosanna Paciucci
Journal:  Oncotarget       Date:  2017-02-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.